about
Comparison of Schistosoma mansoni Prevalence and Intensity of Infection, as Determined by the Circulating Cathodic Antigen Urine Assay or by the Kato-Katz Fecal Assay: A Systematic ReviewA call to strengthen the global strategy for schistosomiasis and soil-transmitted helminthiasis: the time is nowBuilding a global schistosomiasis alliance: an opportunity to join forces to fight inequality and rural povertySchistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs?Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination?Human schistosomiasisImmunology of human schistosomiasis.Schistosoma mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to Immunizations against Hepatitis B and Tetanus ToxoidCountrywide Reassessment of Schistosoma mansoni Infection in Burundi Using a Urine-Circulating Cathodic Antigen Rapid Test: Informing the National Control Program.Workshop report: Schistosomiasis vaccine clinical development and product characteristics.Additional Evaluation of the Point-of-Contact Circulating Cathodic Antigen Assay for Schistosoma mansoni Infection.Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis.Historical perspective: Revisiting the St. Lucia Project, a multi-year comparison trial of schistosomiasis control strategies.New Tools for Old Questions: How Strictly Human Are "Human Schistosomes" - And Does It Matter?Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi.Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya.Effect of four rounds of annual school-wide mass praziquantel treatment for schistosoma mansoni control on schistosome-specific immune responses.Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya.Young Adults in Endemic Areas: An Untreated Group in Need of School-Based Preventive Chemotherapy for Schistosomiasis Control and EliminationWhen Should the Emphasis on Schistosomiasis Control Move to Elimination?Thirty-Day Daily Comparisons of Kato-Katz and CCA Assays of 45 Egyptian Children in Areas with Very Low Prevalence ofDr. Adel A. F. MahmoudMultiple Praziquantel Treatments of Schistosoma mansoni Egg-Negative, CCA-Positive Schoolchildren in a Very Low Endemic Setting in Egypt Do Not Consistently Alter CCA ResultsMapping Schistosoma mansoni endemicity in Rwanda: a critical assessment of geographical disparities arising from circulating cathodic antigen versus Kato-Katz diagnosticsModeling Approaches to Predicting Persistent Hotspots in SCORE Studies for Gaining Control of Schistosomiasis Mansoni in Kenya and TanzaniaPersistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of PraziquantelEnvironmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with PraziquantelFive-Year Impact of Different Multi-Year Mass Drug Administration Strategies on Childhood Schistosoma mansoni-Associated Morbidity: A Combined Analysis from the Schistosomiasis Consortium for Operational Research and Evaluation Cohort Studies in the
P50
Q26769643-32080AAE-310F-4EB5-8BC9-518E147F4515Q29247951-C3D56B98-0F6E-4BB8-8274-90A10B3AB055Q30235143-5D811622-E2BF-4629-85B9-03B1AB53A291Q30235149-6200450A-5307-4366-8FFF-B0C75C1C4D93Q34375673-53BBBBA2-1294-49E5-A65E-006593925CAAQ34413522-E5297E07-EF18-4A5C-8847-6F319DCBF5F8Q34782228-B421CEAD-8AAE-41A9-AE2F-729DFD9810CFQ36214965-CA6E48EB-BC54-474A-9E3B-D510F390D0F0Q37715364-E714D6D8-34D4-47F7-B8D7-3CC38054F018Q39256776-0C6BE44C-5279-4E20-99B0-515CA9BA720BQ39286065-9644C118-77D0-42AE-A2A7-8EA9D2583B6DQ43924383-D4659693-2BD4-49C0-9A27-640EAD013592Q48133840-972A3DD3-80D7-40E0-A42A-E1EACA7D858BQ49819697-FF8700E9-A8F9-485B-81A6-A281B3720B03Q50317536-C67EC0A9-A328-4283-A454-E0CE35BAE945Q50532009-3E6B09F4-17D0-4C89-B4B2-49908C6B7178Q52716945-353B0E33-B10C-4F54-BACE-FBA96CAA1444Q53697118-9FB60152-7C29-469E-BA0B-8701C7FB5EAEQ55500683-12330204-5AE8-4F1A-933D-3AC0CB794F47Q57118095-794FF48B-5860-4F5C-97B0-1B1B5F7EF400Q57133725-4CB753E3-43D4-48A5-B9FD-0095098DBA3DQ64240397-1F2D210C-64AD-4A4E-9A02-6FA891212D67Q89399208-2510ED03-346A-4FEE-9A26-DE728075BD89Q90264518-BA13B45F-B087-453A-81D6-F4AEED187682Q90375189-DD770A28-C248-405D-85B6-BC5CD7337A98Q90767541-A394C7A9-A56A-4F8A-9857-55E02FEE165AQ91735806-E92C7A3C-BAC7-47FA-8042-32123162A25CQ92337933-69D44AD2-B4D2-410A-B8AD-966777C563B7Q92587416-9BA886B9-9F7C-4BC2-9279-AB909F781E14
P50
description
investigador
@es
researcher
@en
name
Daniel G Colley
@en
type
label
Daniel G Colley
@en
prefLabel
Daniel G Colley
@en
P31
P496
0000-0002-9381-8420